Korean Circ J.  2011 Jun;41(6):313-320. 10.4070/kcj.2011.41.6.313.

Prevalence of Echocardiographic Features Suggesting Cardiac Sarcoidosis in Patients With Pacemaker or Implantable Cardiac Defibrillator

• Sun BJ
• Lee PH
• Choi HO
• Ahn JM
• Seo JS
• Kim DH
• Song JM
• Choi KJ
• Kang DH
• Song JK

• KMID: 1776188
• DOI: http://doi.org/10.4070/kcj.2011.41.6.313

Abstract

BACKGROUND AND OBJECTIVES
Basal septal thinning or localized aneurysmal dilatation without coronary artery disease has been described as a characteristic finding suggestive of cardiac sarcoidosis. We sought to assess the prevalence of this characteristic echocardiographic finding in patients with pacemaker (PM) or implantable cardiac defibrillator (ICD).
SUBJECTS AND METHODS
Echocardiography of patients who received PM or ICD were retrospectively analyzed. Patients with marked thinning and akinesia confined to the basal septum (type 1), or posterolateral wall resulting in localized aneurysmal outward bulging (type 2) without history of myocardial infarction or significant coronary stenosis were included for analysis.
RESULTS
Among 1,357 consecutive patients, 21 exhibited suggestive echocardiographic findings (type 1/2=15/6) with a mean ejection fraction of 37+/-11%. The prevalence was 1.2% in the PM group and 4.0% in the ICD group. Only 3 patients showed histologically confirmable sarcoidosis in lymph nodes, lung and heart, respectively. Endomyocardial biopsy was attempted in 6 patients, but failed to demonstrate sarcoidosis. The 1-, 2-, 4- and 6-year clinical events (death, cardiac transplantation and hospital admission)-free survival rates were 100%, 85.7+/-7.6%, 75.0+/-9.7% and 48.6+/-12.4%, respectively. During follow-up, two patients with PM underwent ICD implantation, and another underwent heart transplantation.
CONCLUSION
Prevalence of echocardiographic features suggesting prevalence of cardiac sarcoidosis is low in patients who underwent device implantation. However, considering the very low yield of endomyocardial biopsy and the rare extracardiac manifestations in cardiac sarcoidosis, characteristic echocardiographic findings could be an adjunctive diagnostic criterion in these patients.

Keyword

Sarcoidosis; Echocardiography; Pacemaker; Implantable cardioverter-defibrillators

MeSH Terms

Aneurysm
Biopsy
Coronary Artery Disease
Coronary Stenosis
Defibrillators
Defibrillators, Implantable
Dilatation
Echocardiography
Follow-Up Studies
Heart
Heart Transplantation
Humans
Lung
Lymph Nodes
Myocardial Infarction
Prevalence
Retrospective Studies
Sarcoidosis
Survival Rate

Figure

• 

  Fig. 1 Representative echocardiographic images suggestive of cardiac involvement of sarcoidosis. Type 1 morphologic change is characterized by thinning and akinesia of the basal septum (A and B). Aneurysmal dilatation involving inferior or posterolateral wall is classified as type 2 (C and D).

• 

  Fig. 2 (A) and (C) are computed tomographic images of a 53-year old patient those demonstrate numerous enlarged lymph nodes compressing the adjacent structures. (B) is the echocardiographic image in which the arrow points at the basal septum with thinning. Panel D is a micrograph of a supraclavicular lymph node with non-caseating granuloma (hematoxylin and eosin stain, 200×; Scale bar=100 µm).

• 

  Fig. 3 A 44-year old man who had undergone pacemaker insertion 2 years before due to complete atrio-ventricular block complained of recurrent palpitation and dyspnea. He was diagnosed with atrial flutter and received radiofrequency catheter ablation. (A) Thereafter, thinning of basal septum became more prominent while symptoms of heart failure are more aggravated over the next 16 months. (C) denotes the echocardiography at the time of heart transplantation. (D) is a micrograph showing non-caseating granuloma from tricuspid valve of extracted heart (hematoxylin and eosin stain, 200×; Scale bar=100 µm).

• 

  Fig. 4 Event free survival of the overall group (A), and comparisons with those according to echocardiographic type (B), and the class of cardiac device inserted (C). Adverse clinical events included death, cardiac transplantation, and hospital admission due to cardiac causes during the follow-up period. ICD: implantable cardioverter-defibrillator, PM: pacemaker.

Reference

1. Dubrey SW, Bell A, Mittal TK. Sarcoid heart disease. Postgrad Med J. 2007. 83:618–623.

2. Bargout R, Kelly RF. Sarcoid heart disease: clinical course and treatment. Int J Cardiol. 2004. 97:173–182.

3. Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther. 1996. 10:495–510.

4. Lewin RF, Mor R, Spitzer S, Arditti A, Hellman C, Agmon J. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J. 1985. 110:116–122.

5. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med. 1977. 63:86–108.

6. Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation. 1978. 58:1204–1211.

7. Yamano T, Nakatani S. Cardiac sarcoidosis: what can we know from echocardiography? J Echocardiogr. 2007. 5:1–10.

8. Hiraga H, Yuwai K, Hiroe M. Guidelines for the diagnosis of cardiac sarcoidosis: study report of diffuse pulmonary diseases. 1993. Tokyo: Japanese Ministry of Health and Welfare;23–24.

9. Tawarahara K, Kurata C, Okayama K, Kobayashi A, Yamazaki N. Thallium-201 and gallium 67 single photon emission computed tomographic imaging in cardiac sarcoidosis. Am Heart J. 1992. 124:1383–1384.

10. Tellier P, Paycha F, Antony I, et al. Reversibility by dipyridamole of thallium-201 myocardial scan defects in patients with sarcoidosis. Am J Med. 1988. 85:189–193.

11. Rybicki BA, Major M, Popovich J, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997. 145:234–241.

12. Kim DS. Sarcoidosis in Korea: report of the Second Nationwide Survey. Sarcoidosis Vasc Diffuse Lung Dis. 2001. 18:176–180.

13. Matsui Y, Iwai K, Tachibana T, et al. Clinicopathological study of fatal myocardial sarcoidosis. Ann N Y Acad Sci. 1976. 278:455–469.

14. Siltzbach LE, James DG, Neville E, et al. Course and prognosis of sarcoidosis around the world. Am J Med. 1974. 57:847–852.

15. Choi JH, Kim J, Park TI, et al. Two cases of an implantation of a permanent pacemaker using a transaxillary incision. Korean Circ J. 2008. 38:500–504.

16. Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J. 1999. 138:299–302.

17. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 1999. 16:75–86.

18. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007. 357:2153–2165.

19. Nelson JE, Kirschner PA, Teirstein AS. Sarcoidosis presenting as heart disease. Sarcoidosis Vasc Diffuse Lung Dis. 1996. 13:178–182.

20. Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol. 2005. 95:143–146.

21. Valantine H, McKenna WJ, Nihoyannopoulos P, et al. Sarcoidosis: a pattern of clinical and morphological presentation. Br Heart J. 1987. 57:256–263.

22. Cho Y. Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Korean Circ J. 2008. 38:514–523.